
Individualizing Buprenorphine: Low-dose Induction to Long-acting Injectables
Episode 34
In this episode of ASAM Practice Pearls, Dr. Stephen Taylor hosts Dr. Stephen Holt in a discussion about practical strategies for initiating and managing patients receiving low-dose buprenorphine and long-acting injectable (LAI) formulations. The conversation explores how to match induction approaches to individual patient needs, guidance on dosing, and ways to support ongoing use, cravings, or withdrawal symptoms. This episode offers listeners practical insights for implementing buprenorphine treatment strategies and expanding access to evidence-based care. ----more---- Looking for this episode's transcript? Download it HERE Get credit for listening! Claim your 0.5 CEs HERE Have an idea for a future episode? Share it with us at education@asam.org. Host Stephen M. Taylor, MD, MPH, DFAPA, DFASAM Dr. Stephen M. Taylor is ASAM's President and is board certified in general psychiatry, child and adolescent psychiatry, addiction psychiatry, and addiction medicine. With over 30 years of practice experience, Dr. Taylor is dedicated to helping adolescents and adults overcome addiction and co-occurring psychiatric disorders. He has served as the Medical Director of the NBA and NBPA Player Assistance and Anti-Drug Program for 16 years and is the Chief Medical Officer of Pathway Healthcare, which operates multiple outpatient addiction and mental health treatment offices across six states. Expert Stephen Holt, MD, MS, FACP, FASAM Dr.
Publisher
ASAM Practice Pearls
Link
asampracticepearls.podbean.com/e/individualizing-buprenorphine-low-dose-induction-to-long-acting-injectables/
Published
July 13, 2026
Duration
26 min
Format
Podcast
Category
Lifestyle · Medicine
Source
RSS feed
Host
ASAM Education
ASAM Practice Pearls
@asampracticepearls
#individualizingbuprenorphine #doseinduction #actinginjectables #medicine
